Myeloma Patients Europe (MPE) held a webinar yesterday on myeloma and AL amyloidosis treatment update given by Dr Inger Nijhof, Department of Hematology, VU University Medical Center, Amsterdam, The Netherlands. Continue reading
As part of the educational programme planned to replace the Masterclass included in the MPE Annual General Meeting (AGM) 2020, which was cancelled due to the outbreak of the coronavirus infection, MPE is organising a Webinars series.
Myeloma Patients Europe (MPE) will hold a webinar on myeloma and AL amyloidosis treatment updates on Wednesday 11 March 2020 from 18:30 – 19:30 CET. Continue reading
Myeloma Patients Europe (MPE), in collaboration with the pharmaceutical company Amgen, launched a survey in 2019 for European myeloma patients to understand their treatment information needs. Continue reading
The U.S. Food and Drug Administration (FDA) has approved isatuximab-irfc (Sarclisa®) in combination with pomalidomide and dexamethasone (pom-dex) for the treatment of adults with relapsed refractory myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor. Continue reading
The United Kingdom will formally leave the European Union on 31 January 2020 and will become a third country to the EU. On 1 February 2020 a transition period will start which is due to end on 31 December 2020. Continue reading
Myeloma Patients Europe (MPE) held a webinar yesterday on ASH 2019 myeloma and AL amyloidosis highlights with the aim of reviewing the most recent myeloma findings presented at the annual meeting of the American Society of Hematology (ASH) that took place in Orlando, Florida, USA, in December 2019. Continue reading
Myeloma Patients Europe will hold a webinar to review the most recent myeloma findings presented at the annual meeting of the American Society of Hematology (ASH) that took place in Orlando, Florida, USA, in December 2019. Continue reading
Selinexor is a first-in-class, oral Selective Inhibitor of Nuclear Export (SINE) compound that is approved the United States Food and Drug Administration (FDA) in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma (RRMM) who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors, at least two immunomodulatory agents, and an anti-CD38 monoclonal antibody. During the American Society of Hematology (ASH) Annual Meeting, new results of this myeloma drug were presented. Dr Cristina Gasparetto, Duke Cancer Institute, North Corolina, USA, explains for Myeloma Patients Europe (MPE) the main results of selinexor. Continue reading
Dr Faith Davies, NYU Langone Hospital, New York, USA, explains in this video the pre-clinical myeloma updates presented in the American Society of Hematology (ASH) Annual Meeting 2019 and why are those important to patients. Continue reading